Trial Profile
CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Bicalutamide; Flutamide; Luteinising hormone stimulants; Luteinising hormone stimulants
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CHAARTED
- 14 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Jul 2024.
- 24 Oct 2023 Results comparing treatment regimens androgen deprivation therapy or docetaxel in the control or research arms in mHSPC were utilized from 13 trials which includes (NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646) studies, presented at the 48th European Society for Medical Oncology Congress.
- 06 Jun 2023 Results of post-hoc exploratory analysis trial, the QOL instrument Functional Assessment of Cancer Therapy-Prostate (FACT-P), presented at the 59th Annual Meeting of the American Society of Clinical Oncology.